Summary
The AI response is not a label-aligned answer; it is a meta-classification output (“absent_from_the_label”) that is not supported by evaluating the provided substantive label sections against the listed claims.
Category Scores
Accurate Statements
Unsupported Statements
classification: absent_from_the_label
The prompt contains multiple substantive medical claims about Lipitor/statins liver monitoring and injury; however, the response does not actually map any provided claim to label language, and instead declares a classification result without substantiation. The provided label excerpts (Sections 5.2, 4.1, 17.2) contain several directly relevant statements (biochemical liver abnormalities, incidence of persistent transaminase elevations, monitoring schedule, caution, and contraindication for active liver disease), so classifying the claim set as absent from the label is unsupported by the supplied label text.
Rationale: No specific medical claim was provided to evaluate; therefore cannot evaluate
The prompt does provide specific claims (nine statin/Lipitor liver-monitoring and symptom/urgency statements). The response contradicts the existence of claims to evaluate.
Contradictions
Low
AI Statement
No specific medical claim was provided to evaluate.
Label Reference
User-provided claims (multiple) in the prompt; label excerpts include relevant liver dysfunction/monitoring content in 5.2 and 17.2 and contraindication content in 4.1. The response’s statement conflicts with the prompt content itself.
Important Omissions
Claim-by-claim mapping of each provided medical claim to the supplied label excerpts (5.2, 4.1, 17.2) with citations and determinations of accuracy/omission/contradiction.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because the response fails to perform an actual FDA-label alignment evaluation for the provided medical claims and outputs an unsubstantiated classification (“absent_from_the_label”), it could mislead downstream processes about the label support for liver monitoring/safety statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
The response does not evaluate the provided medical claims against the supplied FDA label excerpts; it outputs a meta-classification that is unsupported by the label text provided.
Suggested Improvement
Replace the meta output with a structured audit that evaluates each listed claim against the supplied label excerpts (5.2 liver dysfunction/monitoring/incidence/caution, 4.1 active liver disease contraindication, and 17.2 liver enzymes monitoring schedule), recording accurate/unsupported/contradictory/omitted elements per claim.